What is Lumigan?
Your eyes' color can gradually change to brown if you use bimatoprost ophthalmic. Even after your treatment is over, these modifications could still last a lifetime and could only affect the iris, the colored portion of your eye. As a result, the iris may develop an uneven coloring, with some areas turning browner than others. If you experience eye discomfort or changes in your vision, call your doctor. The use of bimatoprost may increase your risk of macular edema, or swelling in the retina's center. If you experience sudden vision loss in one or both of your eyes, stop taking this medication and contact your doctor right away. While taking this medication, avoid wearing contact lenses. Wearing contact lenses can be uncomfortable when using bimatoprost ophthalmic.
Take Latanoprost at least 5 minutes before or after taking bimatoprost ophthalmic if you use it.
The body of a person contains trace amounts of the mineral boron. An average person's body contains 2 to 3 grams of boron, according to estimates. Since the body does not need boric acid for any known biological function, it is not regarded as an essential nutrient.
However, some studies indicate that boron may be important for bone health and brain function. Although there isn't much solid scientific evidence to back up these claims, boron supplements are occasionally marketed as a way to treat these conditions.
Tablets, capsules, and powders are just a few of the different forms of boron supplements that are offered. Some multivitamin and mineral products also contain them. When taken as directed, boron supplements are generally considered safe.
(Travatan) travoprost This is not an exhaustive list. Bimatoprost ophthalmic may interact with other medications, including prescription and over-the-counter drugs, vitamins, and herbal products. This list does not include all possible drug interactions.
Certain forms of glaucoma and other causes of high eye pressure are treated with bimatoprost ophthalmic (for the eyes). There are additional uses for bimatoprost ophthalmic besides those that are covered in this medication guide.
After ocular administration, bimatoprost has a low systemic exposure. The mean peak concentration (Cmax) and area under the curve (AUC) of bimatoprost in plasma in a study with 28 patients with open-angle glaucoma or ocular hypertension were both less than 0.1 ng/mL•h and appeared about 5 minutes after dosing. The average half-life of elimination was 45 minutes.
The following side effects were discovered while using bimatoprost ophthalmic solution after receiving approval. It is not always possible to accurately estimate the frequency of these reactions or establish a causal link to drug exposure because these reactions are voluntarily reported from a population with an ambiguous size.
Conjunctival hyperemia was the most frequent adverse reaction associated with the use of bimatoprost ophthalmic solution 0.03%, occurring in about 4% of patients in clinical trials. A decrease in visual acuity, iritis/uveitis, eye pain/discomfort, increased lacrimation, and other common adverse reactions (affecting 1% to 3% of patients) are also common. Bimatoprost ophthalmic solution 0.03% post-marketing experience has revealed the following additional adverse reactions. Within each category, these responses are listed in decreasing frequency order.
Dosage and Administration
In plastic bottles, sterile, preservative-free aqueous solution of 0.3 mg/mL bimatoprost-free base is provided as bimatoprost ophthalmic solution 0.03%:
7.5 mL contained in a white low-density polyethylene (LDPE) bottle with a natural HDPE dispensing plug and a white polypropylene cap bearing codes TZC on the plug and 5AL on the cap (NDC 0023-0111-05).
The 15 mL container has a white LDPE bottle with a natural HDPE dispensing plug and a white polypropylene cap with the codes TZC and 5AM (NDC 0023-0111-15).
Each milliliter of the solution has a 0.3 mg bimatoprost-free base in it, which is equivalent to 0.3386 mg of the active ingredient bimatoprost. Mannitol, sodium chloride, and disodium phosphate anhydrous are also included in Water for Injection. Using hydrochloric acid, the pH is raised to 7.8 0.2. Osmolality and tonicity of bimatoprost ophthalmic solution are roughly 290 and 270 mOsm/mL and kg, respectively. Since it doesn't contain any preservatives, once opened, it must be consumed within four weeks.
There haven't been any reports of human overdoses on Lumigan. In the event of an overdose, general supportive care is recommended. If dialysis is thought of, it might not be an efficient way to get rid of the medication because bimatoprost is highly protein bound.
The recommended storage range for bimatoprost ophthalmic solution 0.03% is 15°C to 25°C (59°F to 77°F). shield against light. Avoid freezing. Use the solution within four weeks of opening it. After 4 weeks of opening the bottle, throw away any unused solution.